腎バイオマーカーの世界市場2016-2026

◆英語タイトル:Renal Biomarker Market: Rising Prevalence of Renal Diseases Fuelling Demand for Renal Biomarkers: Global Industry Analysis and Opportunity Assessment, 2016-2026
◆商品コード:FMI703019
◆発行会社(調査会社):Future Market Insights
◆発行日:2016年11月22日
◆ページ数:190
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual (single user)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
EnterpriseUSD10,000 ⇒換算¥1,130,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。
本調査レポートでは、腎バイオマーカーの世界市場について調査・分析し、腎バイオマーカーの世界市場動向、腎バイオマーカーの世界市場規模、市場予測、セグメント別腎バイオマーカー市場分析、地域別市場規模(北米市場、南米市場、アジア市場、日本市場、ヨーロッパ市場など)、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

Kidney diseases are one of the leading causes of death worldwide. The incidence of chronic kidney diseases is rapidly rising especially in the elderly population due to increase in life expectancy of general population and improvements in medical management services. However, diabetes and hypertension remain the leading cause of renal diseases. Biomarkers are measurable indicators reflecting physiological and pharmacological progression of disease state. Recent advances in molecular biology have resulted in the development of novel biomarkers for the renal function. Extensive R&D by biomarker manufacturers has led to identification of novel renal biomarkers to deliver better diagnostic accuracy and improve patient outcomes.
Market forecast

Revenue from the global renal biomarker market is projected to register a CAGR of 7.0% during the forecast period (2016 – 2026) and reach a market valuation of US$ 1,770.3 Mn by the end of 2026.

Rising prevalence of renal diseases primary driver boosting market growth

Growth of the global renal biomarker market is mainly driven by rising prevalence of various renal diseases coupled with an ageing population worldwide. Also, there has been an increase in the adult population with chronic kidney diseases, primarily attributed to a rising prevalence of conditions such as diabetes and high blood pressure. Other prominent growth factors include large number of clinical trials in the novel renal biomarker and drug development space and penetration of various cost-effective, reliable, and rapid technologically driven diagnostic protocols in clinical practice. However, use of unreliable imperfect gold standard for renal disease diagnosis and lack of sensitivity and specificity in current renal biomarkers are some of the factors restraining the growth of the market over the forecast period.

Current trends governing the global renal biomarker market include the possible use of renal biomarkers in personalised medicine and drug development and a growing popularity of non-invasive renal biomarkers.

Functional Biomarker type segment expected to remain the dominant segment over the forecast period

The Functional Biomarker segment is anticipated to account for a market value share of 52.3% by the end of 2016 and is expected to retain its dominance throughout the forecast period. The Up-Regulated Proteins segment is estimated to account for 33.8% market share in terms of value by 2016 end.

Enzyme Linked Immunosorbent Assay diagnostic technique segment estimated to hold the highest market share throughout the forecast period

The Enzyme Linked Immunosorbent Assay segment is anticipated to register a CAGR of 8.1% over the forecast period and is expected to register high Y-o-Y growth rates from 2016 to 2026. The Particle-Enhanced Turbidimetric Immunoassay segment is estimated to be the second largest segment in terms of value, holding a market value share of 21.0% by 2016 end.

Diagnostic Labs end user segment expected to witness highest growth in terms of revenue throughout the forecast period

The Diagnostic Labs segment is estimated to account for 34.2% market share of the global renal biomarker market in revenue terms by 2016 end and is expected to register high Y-o-Y growth rates throughout the forecast period. The Outpatient Clinics segment is anticipated to register a CAGR of 7.2% during the forecast period.

North America renal biomarker market expected to register high Y-o-Y growth throughout the forecast period

The North America regional market is estimated to account for 32.2% revenue share of the global renal biomarker market by 2016 end. Western Europe is estimated to hold the second largest market share of 21.1% by 2016 end.

Leading market players are emphasising on product innovation and strategic acquisitions to increase market share

Beckman Coulter, Inc. (Danaher Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S, Astute Medical, Inc., and Randox Laboratories Ltd. are some of the key players operating in the global renal biomarker market. Top market companies are focussing on increasing their presence in high-growth emerging markets through structured investments in R&D and technological innovation.

【レポートの目次】

Table Of Content

1. Executive Summary

2. Market Introduction

2.1. Market Definition

2.2. Market Taxonomy

3. Global Renal Biomarker Market Analysis Scenario

3.1. Market Size (US$ Mn) and Forecast

3.1.1. Market Size and Y-o-Y Growth

3.1.2. Absolute $ Opportunity

3.2. Market Overview

4. Market Dynamics

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Forecast Factors – Relevance and Impact

4.6. Diseases Epidemiology

5. Global Renal Biomarker Market Analysis and Forecasts, By Biomarker Type

5.1. Introduction

5.2. Basis Point Share (BPS) Analysis By Biomarker Type

5.3. Y-o-Y Growth Projections By Biomarker Type

5.4. Market Value Forecast By Biomarker Type , 2015–2026

5.4.1. Functional Biomarker

5.4.1.1. Serum Creatinine

5.4.1.2. Serum Cystatin C

5.4.1.3. Urine Albumin

5.4.2. Up-Regulated Proteins

5.4.2.1. Neutrophil Gelatinase-Associated Lipocalin

5.4.2.2. Kidney Injury Molecule-1

5.4.2.3. Interleukin-18

5.4.3. Others

5.5. Prominent Trends

5.6. Market Attractiveness By Biomarker Type

6. Global Renal Biomarker Market Analysis and Forecasts, By Diagnostic Technique

6.1. Introduction

6.2. Basis Point Share (BPS) Analysis By Diagnostic Technique

6.3. Y-o-Y Growth Projections By Diagnostic Technique

6.4. Market Value Forecast By Diagnostic Technique , 2015–2026

6.4.1. Enzyme Linked Immunosorbent Assay (ELISA)

6.4.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

6.4.3. Colorimetric Assay

6.4.4. Chemiluminescent Enzyme Immunoassay (CLIA)

6.4.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

6.5. Prominent Trends

6.6. Market Attractiveness By Diagnostic Technique

7. Global Renal Biomarker Market Analysis and Forecasts, By End User

7.1. Introduction

7.2. Basis Point Share (BPS) Analysis By End User

7.3. Y-o-Y Growth Projections By End User

7.4. Market Value Forecast By End User , 2015–2026

7.4.1. Diagnostic Labs

7.4.2. Outpatient Clinics

7.4.3. Research Centers

7.4.4. Hospitals

7.5. Prominent Trends

7.6. Market Attractiveness By End User

8. Global Renal Biomarker Market Analysis and Forecasts, By Region

8.1. Basis Point Share (BPS) Analysis By Country

8.2. Y-o-Y Growth Projections By Country

8.3. Market Value Forecast By Region

8.3.1. North America

8.3.2. Latin America

8.3.3. Western Europe

8.3.4. Eastern Europe

8.3.5. Asia Pacific Excluding Japan (APEJ)

8.3.6. Japan

8.3.7. Middle East and Africa (MEA)

8.4. Market Attractiveness By Country/Region

9. North America Renal Biomarker Market Analysis and Forecast

9.1. Introduction

9.1.1. Basis Point Share (BPS) Analysis By Country

9.1.2. Y-o-Y Growth Projections By Country

9.1.3. Key Regulations

9.2. Market Value Forecast By Biomarker Type , 2015–2026

9.2.1. Functional Biomarker

9.2.1.1. Serum Creatinine

9.2.1.2. Serum Cystatin C

9.2.1.3. Urine Albumin

9.2.2. Up-Regulated Proteins

9.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

9.2.2.2. Kidney Injury Molecule-1

9.2.2.3. Interleukin-18

9.2.3. Others

9.3. Market Value Forecast By Diagnostic Technique , 2015–2026

9.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

9.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

9.3.3. Colorimetric Assay

9.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

9.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

9.4. Market Value Forecast By End User , 2015–2026

9.4.1. Diagnostic Labs

9.4.2. Outpatient Clinics

9.4.3. Research Centers

9.4.4. Hospitals

9.5. Market Value Forecast By Country , 2015–2026

9.5.1. The U.S.

9.5.2. Canada

9.6. Market Attractiveness Analysis

9.6.1. By Biomarker Type

9.6.2. By Diagnostic Technique

9.6.3. By End User

9.6.4. By Country

9.7. Prominent Trends

9.8. Drivers and Restraints: Impact Analysis

10. Latin America Renal Biomarker Market Analysis and Forecast

10.1.Introduction

10.1.1. Basis Point Share (BPS) Analysis By Country

10.1.2. Y-o-Y Growth Projections By Country

10.1.3. Key Regulations

10.2.Market Value Forecast By Biomarker Type , 2015–2026

10.2.1. Functional Biomarker

10.2.1.1. Serum Creatinine

10.2.1.2. Serum Cystatin C

10.2.1.3. Urine Albumin

10.2.2. Up-Regulated Proteins

10.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

10.2.2.2. Kidney Injury Molecule-1

10.2.2.3. Interleukin-18

10.2.3. Others

10.3.Market Value Forecast By Diagnostic Technique , 2015–2026

10.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

10.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

10.3.3. Colorimetric Assay

10.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

10.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

10.4.Market Value Forecast By End User , 2015–2026

10.4.1. Diagnostic Labs

10.4.2. Outpatient Clinics

10.4.3. Research Centers

10.4.4. Hospitals

10.5.Market Value Forecast By Country , 2015–2026

10.5.1. Brazil

10.5.2. Mexico

10.5.3. Rest of Latin America

10.6.Market Attractiveness Analysis

10.6.1. By Biomarker Type

10.6.2. By Diagnostic Technique

10.6.3. By End User

10.6.4. By Country

10.7. Prominent Trends

10.8. Drivers and Restraints: Impact Analysis

11. Western Europe Renal Biomarker Market Analysis and Forecast

11.1.Introduction

11.1.1. Basis Point Share (BPS) Analysis By Country

11.1.2. Y-o-Y Growth Projections By Country

11.1.3. Key Regulations

11.2.Market Value Forecast By Biomarker Type , 2015–2026

11.2.1. Functional Biomarker

11.2.1.1. Serum Creatinine

11.2.1.2. Serum Cystatin C

11.2.1.3. Urine Albumin

11.2.2. Up-Regulated Proteins

11.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

11.2.2.2. Kidney Injury Molecule-1

11.2.2.3. Interleukin-18

11.2.3. Others

11.3.Market Value Forecast By Diagnostic Technique , 2015–2026

11.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

11.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

11.3.3. Colorimetric Assay

11.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

11.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

11.4.Market Value Forecast By End User , 2015–2026

11.4.1. Diagnostic Labs

11.4.2. Outpatient Clinics

11.4.3. Research Centers

11.4.4. Hospitals

11.5.Market Value Forecast By Country , 2015–2026

11.5.1. Germany

11.5.2. France

11.5.3. Italy

11.5.4. Spain

11.5.5. The U.K.

11.5.6. BENELUX

11.5.7. Rest of Western Europe

11.6.Market Attractiveness Analysis

11.6.1. By Biomarker Type

11.6.2. By Diagnostic Technique

11.6.3. By End User

11.6.4. By Country

11.7. Prominent Trends

11.8. Drivers and Restraints: Impact Analysis

12. Eastern Europe Renal Biomarker Market Analysis and Forecast

12.1.Introduction

12.1.1. Basis Point Share (BPS) Analysis By Country

12.1.2. Y-o-Y Growth Projections By Country

12.1.3. Key Regulations

12.2.Market Value Forecast By Biomarker Type , 2015–2026

12.2.1. Functional Biomarker

12.2.1.1. Serum Creatinine

12.2.1.2. Serum Cystatin C

12.2.1.3. Urine Albumin

12.2.2. Up-Regulated Proteins

12.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

12.2.2.2. Kidney Injury Molecule-1

12.2.2.3. Interleukin-18

12.2.3. Others

12.3.Market Value Forecast By Diagnostic Technique , 2015–2026

12.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

12.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

12.3.3. Colorimetric Assay

12.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

12.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

12.4.Market Value Forecast By End User , 2015–2026

12.4.1. Diagnostic Labs

12.4.2. Outpatient Clinics

12.4.3. Research Centers

12.4.4. Hospitals

12.5.Market Value Forecast By Country , 2015–2026

12.5.1. Russia

12.5.2. Poland

12.5.3. Rest of Eastern Europe

12.6.Market Attractiveness Analysis

12.6.1. By Biomarker Type

12.6.2. By Diagnostic Technique

12.6.3. By End User

12.6.4. By Country

12.7. Prominent Trends

12.8. Drivers and Restraints: Impact Analysis

13. Asia Pacific Excluding Japan (APEJ) Renal Biomarker Market Analysis and Forecast

13.1.Introduction

13.1.1. Basis Point Share (BPS) Analysis By Country

13.1.2. Y-o-Y Growth Projections By Country

13.1.3. Key Regulations

13.2.Market Value Forecast By Biomarker Type , 2015–2026

13.2.1. Functional Biomarker

13.2.1.1. Serum Creatinine

13.2.1.2. Serum Cystatin C

13.2.1.3. Urine Albumin

13.2.2. Up-Regulated Proteins

13.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

13.2.2.2. Kidney Injury Molecule-1

13.2.2.3. Interleukin-18

13.2.3. Others

13.3.Market Value Forecast By Diagnostic Technique , 2015–2026

13.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

13.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

13.3.3. Colorimetric Assay

13.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

13.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

13.4.Market Value Forecast By End User , 2015–2026

13.4.1. Diagnostic Labs

13.4.2. Outpatient Clinics

13.4.3. Research Centers

13.4.4. Hospitals

13.5.Market Value Forecast By Country , 2015–2026

13.5.1. China

13.5.2. India

13.5.3. ASEAN

13.5.4. Australia and New Zealand

13.5.5. Rest of APEJ

13.6.Market Attractiveness Analysis

13.6.1. By Biomarker Type

13.6.2. By Diagnostic Technique

13.6.3. By End User

13.6.4. By Country

13.7. Prominent Trends

13.8. Drivers and Restraints: Impact Analysis

14. Japan Renal Biomarker Market Analysis and Forecast

14.1.Introduction

14.1.1. Basis Point Share (BPS) Analysis By Country

14.1.2. Y-o-Y Growth Projections By Country

14.1.3. Key Regulations

14.2.Market Value Forecast By Biomarker Type , 2015–2026

14.2.1. Functional Biomarker

14.2.1.1. Serum Creatinine

14.2.1.2. Serum Cystatin C

14.2.1.3. Urine Albumin

14.2.2. Up-Regulated Proteins

14.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

14.2.2.2. Kidney Injury Molecule-1

14.2.2.3. Interleukin-18

14.2.3. Others

14.3.Market Value Forecast By Diagnostic Technique , 2015–2026

14.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

14.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

14.3.3. Colorimetric Assay

14.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

14.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

14.4.Market Value Forecast By End User , 2015–2026

14.4.1. Diagnostic Labs

14.4.2. Outpatient Clinics

14.4.3. Research Centers

14.4.4. Hospitals

14.5.Market Attractiveness Analysis

14.5.1. By Biomarker Type

14.5.2. By Diagnostic Technique

14.5.3. By End User

14.6. Prominent Trends

14.7. Drivers and Restraints: Impact Analysis

15. Middle East and Africa (MEA) Renal Biomarker Market Analysis and Forecast

15.1.Introduction

15.1.1. Basis Point Share (BPS) Analysis By Country

15.1.2. Y-o-Y Growth Projections By Country

15.1.3. Key Regulations

15.2.Market Value Forecast By Biomarker Type , 2015–2026

15.2.1. Functional Biomarker

15.2.1.1. Serum Creatinine

15.2.1.2. Serum Cystatin C

15.2.1.3. Urine Albumin

15.2.2. Up-Regulated Proteins

15.2.2.1. Neutrophil Gelatinase-Associated Lipocalin

15.2.2.2. Kidney Injury Molecule-1

15.2.2.3. Interleukin-18

15.2.3. Others

15.3.Market Value Forecast By Diagnostic Technique , 2015–2026

15.3.1. Enzyme Linked Immunosorbent Assay (ELISA)

15.3.2. Particle-Enhanced Turbidimetric Immunoassay (PETIA)

15.3.3. Colorimetric Assay

15.3.4. Chemiluminescent Enzyme Immunoassay (CLIA)

15.3.5. Liquid Chromatography-Mass Spectrometry (LS-MS)

15.4.Market Value Forecast By End User , 2015–2026

15.4.1. Diagnostic Labs

15.4.2. Outpatient Clinics

15.4.3. Research Centers

15.4.4. Hospitals

15.5.Market Value Forecast By Country , 2015–2026

15.5.1. GCC

15.5.2. South Africa

15.5.3. Rest of MEA

15.6.Market Attractiveness Analysis

15.6.1. By Biomarker Type

15.6.2. By Diagnostic Technique

15.6.3. By End User

15.6.4. By Country

15.7. Prominent Trends

15.8. Drivers and Restraints: Impact Analysis

16. Competition Landscape

16.1.Competition Dashboard

16.2.Market Share Analysis By Company (2015)

16.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

16.3.1. Beckman Coulter, Inc. (Danaher Corporation)

16.3.2. Thermo Fisher Scientific Inc.

16.3.3. Abbott Laboratories

16.3.4. BIOPORTO A/S

16.3.5. Astute Medical, Inc.

16.3.6. Randox Laboratories Ltd.



【レポートのキーワード】

腎バイオマーカー、腎障害バイオマーカー

★調査レポート[腎バイオマーカーの世界市場2016-2026] (コード:FMI703019)販売に関する免責事項を必ずご確認ください。
★調査レポート[腎バイオマーカーの世界市場2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆